The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
NGM Bio and KdT Ventures Enter Worldwide License Agreement for NGM313
Dec 19, 2024•over 1 year ago
Contract Type
agreement
San FranciscoBiotechnologyHealth CareTherapeutics
Description
NGM Bio and KdT Ventures have entered into a worldwide license agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho agonist drug candidate. NGM Bio will receive up to $608 million in upfront and potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales and equity in the new company. KdT Ventures has formed a new company to develop NGM313 in a rare disease indication.
Company Information
Company
NGM Bio
Location
San Francisco, California, United States
About
NGM Bio is a biotech company focused on developing innovative therapies for serious, rare conditions with significant unmet patient needs. The company aims to address underlying biological mechanisms of diseases such as primary sclerosing cholangitis (PSC) and hyperemesis gravidarum (HG) to provide potential treatment options. NGM Bio is committed to advancing clinical development efforts to benefit patients with rare conditions.
San FranciscoBiotechnologyHealth CareTherapeutics